- Home
- UHS vs BMRN Comparison
UHS vs BMRN Comparison
Compare UHS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHS | BMRN |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 10.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | UHS | BMRN |
|---|---|---|
| Price | $231.02 | $53.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $232.58 | $88.42 |
| AVG Volume (30 Days) | 663.8K | ★ 3.0M |
| Earning Date | 10-27-2025 | 10-27-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | 39.76 | ★ 59.53 |
| EPS | ★ 21.01 | 2.68 |
| Revenue | ★ $16,992,503,000.00 | $3,094,001,000.00 |
| Revenue This Year | $10.93 | $13.39 |
| Revenue Next Year | $4.96 | $7.57 |
| P/E Ratio | ★ $11.00 | $19.92 |
| Revenue Growth | 10.21 | ★ 12.39 |
| 52 Week Low | $152.33 | $50.76 |
| 52 Week High | $246.33 | $73.51 |
Technical Indicators
Market Signals| Indicator | UHS | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 46.19 |
| Support Level | $228.00 | $53.03 |
| Resistance Level | $246.33 | $54.66 |
| Average True Range (ATR) | 5.99 | 1.45 |
| MACD | -1.35 | -0.11 |
| Stochastic Oscillator | 37.86 | 31.61 |
Price Performance
Historical ComparisonAbout UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.